It could be a case of mind over medicine.

The NHS in Scotland is investigating whether a Buddhist technique similar to meditation can help diabetics manage their condition.

Patients suffering from type one diabetes will be asked to attend a "mindfulness" course once a week where they learn to live in the moment.

Then researchers, from Aberdeen and Greater Glasgow and Clyde, will examine if this new way of life lowers their blood glucose levels and reduces anxiety and depression.

Some patients with diabetes can find it difficult to carry out the complex tasks they have to repeat several times a day to regulate their blood glucose levels.

About one third of adults with diabetes experience significant levels of anxiety and depression which can make it harder for them to effectively manage their condition.

Chief investigator on the project Dr Andy Keen, a health psychologist specialising in diabetes at NHS Grampian, said: "For example, people who are anxious have high levels of stress hormones such as adrenalin and cortisol, and these cause glucose to be released into the bloodstream, driving up blood glucose levels. "Also, depression is characterised by fatigue and low motivation, which can make it tricky to devote the time and energy required to manage complex long-term conditions like diabetes."

Worrying and planning for future catastrophes which will probably never happen and ruminating on imagined failings in the past are features of anxiety and depression, added Dr Keen - who also works for Aberdeen University.

He continued: “It is best to think of mindfulness as a skill. It is a way of helping people be better able to focus on the ‘here and now’ of their lives, and disengage with unhelpful ways of thinking, such as worry and rumination.

“If you change the way people think, then you change the way they feel."

A specially designed mindfulness-based cognitive therapy course has been shown in informal testing by psychologists in NHS Grampian to reduce anxiety and depression symptoms in people with diabetes. The pilot study will explore the effect of this treatment among adults with Type 1 diabetes, whose blood glucose levels are markedly higher than recommended.